Nexus Surgical

Which are the latest news on Nexus Surgical?

Should I buy, sell or hold Nexus Surgical and Medicare Ltd?

Why is Nexus Surgical and Medicare Ltd falling/rising?

As of 09-Jul, the stock price of Nexus Surgical and Medicare Ltd is currently Rs 20.50, reflecting a 6.82% decline after a trend reversal. Despite increased investor participation, the stock is underperforming and showing signs of downward pressure.

As of 09-Jul, the stock price of Nexus Surgical and Medicare Ltd is falling, currently at Rs 20.50, which reflects a decrease of Rs 1.5 or 6.82%. This decline comes after a trend reversal, as the stock has fallen following three consecutive days of gains. Today, the stock underperformed its sector by 7.95% and reached an intraday low of Rs 20, marking a drop of 9.09%. <BR><BR>Despite the recent volatility, where the stock exhibited an intraday volatility of 5.21%, it has been trading in a wide range of Rs 2.2. Additionally, while the stock's moving averages are higher than the 5-day, 20-day, 100-day, and 200-day averages, it is lower than the 50-day moving average, indicating some weakness in the short-term trend. <BR><BR>On a positive note, there has been a significant increase in investor participation, with delivery volume rising by 203.77% compared to the 5-day average. However, the overall performance today and the recent trend reversal suggest that the stock is currently experiencing downward pressure.

How big is Nexus Surgical?

As of 10th June, Nexus Surgical has a market capitalization of 11.00 Cr, with recent net sales of 7.88 Cr and a net profit of 0.73 Cr. Shareholder's funds are 1.06 Cr, and total assets amount to 2.27 Cr.

As of 10th June, Nexus Surgical and Medicare Ltd has a market capitalization of 11.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Nexus Surgical reported Net Sales of 7.88 Cr and a Net Profit of 0.73 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 1.06 Cr and Total Assets of 2.27 Cr.

Who are in the management team of Nexus Surgical?

The management team of Nexus Surgical includes Ram Swaroop Mahadev Joshi (Whole Time Director & CFO), Pawan Choudhary (Executive Director), and independent non-executive directors Rajesh Sodhani, Avinash Kumar Ardawatia, and Neha Kailash Bhageria.

The management team of Nexus Surgical includes the following individuals:<BR><BR>1. Ram Swaroop Mahadev Joshi - Whole Time Director & CFO<BR>2. Pawan Choudhary - Executive Director<BR>3. Rajesh Sodhani - Independent Non-Executive Director<BR>4. Avinash Kumar Ardawatia - Independent Non-Executive Director<BR>5. Neha Kailash Bhageria - Independent Non-Executive Director<BR><BR>If you have any more questions about Nexus Surgical or its management, feel free to ask!

Who are the peers of the Nexus Surgical?

Nexus Surgical's peers include SRG Fingrow Fin, Kinetic Trust, First Custodian, Anjani Finance, and others. While Nexus has below average management risk and average growth, it boasts an excellent capital structure, with a 1-year return of 11.61%, lower than Kinetic Trust's 52.31% but higher than First Custodian's -38.84%.

Peers: The peers of Nexus Surgical are SRG Fingrow Fin, Kinetic Trust, First Custodian, Anjani Finance, CitiPort Fin., Northlink Fiscal, Octal Credit Cap, Pyxis Finvest, Scintilla Comm, and Rajputana Invest.<BR><BR>Quality Snapshot: Excellent management risk is observed at SRG Fingrow Fin, Kinetic Trust, First Custodian, Anjani Finance, Octal Credit Cap, Pyxis Finvest, and Rajputana Invest, while Below Average management risk is found at Nexus Surgical. Growth ratings show Good growth at Anjani Finance, Average growth at Kinetic Trust, First Custodian, and Nexus Surgical, and Below Average growth at SRG Fingrow Fin, Octal Credit Cap, and Pyxis Finvest, and the rest. Excellent capital structure is noted for SRG Fingrow Fin, Kinetic Trust, First Custodian, Anjani Finance, CitiPort Fin., Northlink Fiscal, Octal Credit Cap, Pyxis Finvest, and Rajputana Invest, while Nexus Surgical has an Excellent capital structure.<BR><BR>Return Snapshot: Kinetic Trust has the highest 1-year return at 52.31%, while First Custodian has the lowest at -38.84%, with Nexus Surgical's 1-year return at 11.61% being higher than First Custodian's but lower than Kinetic Trust's. Additionally, peers such as First Custodian, CitiPort Fin., and Rajputana Invest have negative six-month returns.

What does Nexus Surgical do?

Nexus Surgical and Medicare Ltd trades in medical essentials and operates as a micro-cap company in the NBFC sector. It reported net sales of 2 Cr and a net profit of 0 Cr for the quarter ending March 2026, with a market cap of INR 11 Cr.

Overview: <BR>Nexus Surgical and Medicare Ltd is engaged in the trading of medical essentials and operates within the Non Banking Financial Company (NBFC) industry, classified as a micro-cap company.<BR><BR>History: <BR>The company was incorporated in 1992 and was formerly known as Nexus Commodities and Technologies Ltd. It has undergone status changes and came out with a public issue in August 1996 to part-finance its project. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 2 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 11 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 15.00 <BR>Industry P/E: 20 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: 40.56% <BR>Price-to-Book: 6.08 <BR><BR>Contact Details: <BR>Address: Gala No 4 Saarthak Bldg No 1, Square Industrial Park Palghar Maharashtra : 401208 <BR>Email: nexuscom99@gmail.com <BR>Website: http://www.nexusmed.co.in

Are Nexus Surgical and Medicare Ltd latest results good or bad?

Nexus Surgical's latest results show strong profitability with a net profit increase of 41.18% quarter-over-quarter, but a concerning 30.03% decline in net sales raises questions about revenue stability. Investors should be cautious and monitor the company's ability to stabilize its revenue streams.

Nexus Surgical's latest results present a mixed picture. On one hand, the company achieved a net profit of ₹0.24 crores in Q4 FY26, which is a significant improvement of 41.18% compared to the previous quarter and a remarkable 166.67% increase year-on-year. This indicates strong profitability growth and improved operational efficiency, as evidenced by a PAT margin that rose to 11.71%.<BR><BR>However, the net sales for the same quarter saw a substantial decline of 30.03% compared to the previous quarter, dropping to ₹2.05 crores. While this represents a year-on-year increase of 38.51%, the sequential drop highlights volatility in revenue generation, which is a concern for the company's stability.<BR><BR>Overall, while the profitability metrics are encouraging, the erratic nature of revenue growth raises questions about the sustainability of this performance. Investors should be cautious and monitor whether the company can stabilize its revenue streams moving forward.

When is the next results date for Nexus Surgical and Medicare Ltd?

The next results date for Nexus Surgical and Medicare Ltd is 14 February 2026.

The next results date for Nexus Surgical and Medicare Ltd is scheduled for 14 February 2026.

How has been the historical performance of Nexus Surgical?

Nexus Surgical has shown significant growth in net sales and profitability, with net sales increasing from 1.55 Cr in March 2023 to 5.72 Cr in March 2025, and profit after tax rising from 0.17 Cr to 0.50 Cr, while maintaining zero debt. The company's operating profit margin improved, reflecting a positive financial trajectory overall.

Answer:<BR>The historical performance of Nexus Surgical shows a significant upward trend in net sales and profitability over the past few years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Nexus Surgical's net sales have increased from 1.55 Cr in March 2023 to 5.72 Cr in March 2025, indicating strong growth. Total operating income followed a similar trend, rising from 1.55 Cr in March 2023 to 5.72 Cr in March 2025. The company's total expenditure also grew, reaching 5.06 Cr in March 2025, up from 1.34 Cr in March 2023. Despite this increase, the operating profit (PBDIT) improved from 0.21 Cr in March 2023 to 0.67 Cr in March 2025, reflecting a healthier operating profit margin of 11.54% in March 2025 compared to 13.55% in March 2023. Profit before tax also rose from 0.23 Cr in March 2023 to 0.67 Cr in March 2025, with profit after tax increasing from 0.17 Cr to 0.50 Cr over the same period. The earnings per share (EPS) improved significantly from 0.31 in March 2023 to 0.91 in March 2025. On the balance sheet, total assets increased from 0.91 Cr in March 2023 to 2.27 Cr in March 2025, while total liabilities rose from 0.91 Cr to 2.27 Cr in the same timeframe. The company has maintained zero debt throughout this period. Overall, Nexus Surgical's financial performance demonstrates a positive trajectory in sales, profitability, and asset growth.

Who are the top shareholders of the Nexus Surgical?

The top shareholders of Nexus Surgical are Mildred Mercantile Private Limited with 18.55%, Harivardhan Steel & Alloys Private Limited at 16.01%, and individual investors holding a combined 44.64%. There are no institutional holdings in the company.

The top shareholders of Nexus Surgical include Mildred Mercantile Private Limited, which holds the highest promoter stake at 18.55%. The next significant public shareholder is Harivardhan Steel & Alloys Private Limited, with a holding of 16.01%. Additionally, individual investors collectively hold 44.64% of the company's shares. There are no institutional holdings reported, as mutual funds and foreign institutional investors do not hold any shares in Nexus Surgical.

Is Nexus Surgical overvalued or undervalued?

As of November 15, 2023, Nexus Surgical is considered very expensive and overvalued with a PE ratio of 9.23, an EV to EBIT ratio of 8.90, and a high ROE of 47.17%, but it has underperformed the Sensex by 37.39% year-to-date.

As of 15 November 2023, Nexus Surgical's valuation grade has moved from risky to very expensive, indicating a significant shift in its market perception. The company is currently deemed overvalued. Key ratios include a PE ratio of 9.23, an EV to EBIT ratio of 8.90, and a ROE of 47.17%. These figures suggest that while the company has a high return on equity, its valuation metrics are not compelling when compared to peers.<BR><BR>In comparison to its industry peers, Nexus Surgical's PE ratio of 9.23 is lower than Life Insurance's PE of 12.54, but significantly higher than Bajaj Finance's PE of 35.01, which is categorized as very expensive. The PEG ratio of 0.07 also highlights that the stock may not be justified at its current price given its growth prospects. Additionally, Nexus Surgical has underperformed the Sensex over various time frames, particularly year-to-date, where it has declined by 37.39% compared to the Sensex's gain of 5.59%.

What is the technical trend for Nexus Surgical?

As of June 4, 2025, Nexus Surgical's trend is mildly bearish due to daily moving averages, despite mixed signals from weekly and monthly indicators, with the stock down 6.39% over the past week.

As of 4 June 2025, the technical trend for Nexus Surgical has changed from sideways to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating a bearish trend. The weekly MACD and KST are mildly bullish, but the monthly MACD and KST are mildly bearish, suggesting mixed signals across different time frames. The Bollinger Bands are mildly bullish on both weekly and monthly charts, but this is overshadowed by the bearish daily moving averages. Overall, the strength of the bearish trend is supported by the recent price action, with the stock down 6.39% over the past week, contrasting with a positive return from the Sensex.

Has Nexus Surgical declared dividend?

No Dividend History Available